Valuation: Novartis AG

Market Cap 301B 258B 241B 220B 416B 28,770B 420B 2,850B 1,108B 14,446B 1,128B 1,104B 47,801B P/E 2026 *
22.5x
P/E 2027 * 19.2x
Enterprise Value 333B 286B 267B 244B 461B 31,899B 466B 3,160B 1,229B 16,016B 1,251B 1,224B 52,999B EV / Sales 2026 *
5.78x
EV / Sales 2027 * 5.36x
Free-Float
91.66%
Yield 2026 *
2.76%
Yield 2027 * 2.88%
1 day-0.53%
1 week+4.73%
Current month+1.20%
1 month+1.20%
3 months+3.95%
6 months-4.06%
Current year+14.62%
1 week 153.38
Extreme 153.38
160.81
1 month 149.09
Extreme 149.09
160.81
Current year 135.55
Extreme 135.55
170.46
1 year 121.57
Extreme 121.57
170.46
3 years 92.19
Extreme 92.19
170.46
5 years 74.09
Extreme 74.09
170.46
10 years 66.93
Extreme 66.93
170.46
Manager TitleAgeSince
Chief Executive Officer 50 2018-01-31
Director of Finance/CFO - 2026-03-15
Compliance Officer 58 2025-04-13
Director TitleAgeSince
Director/Board Member 67 2014-12-31
Director/Board Member 69 2015-12-31
Director/Board Member 61 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%+4.73% - - 302B
-0.67%+5.66%+75.21%+125.34% 1,119B
+1.04%+4.87%+52.29%+65.95% 651B
-0.17%+6.04%+25.60%+79.85% 468B
-1.38%+4.31%+41.64%+41.08% 374B
-0.52%+3.53%+24.32%+40.27% 302B
-1.06%+5.67%+1.19%+12.44% 259B
+1.03%+6.90%+51.11%+72.46% 238B
-0.53%+1.54%-17.77%-54.10% 208B
+0.42%+6.06%+27.86%+90.47% 181B
Average -0.24%+5.17%+31.27%+52.64% 422.21B
Weighted average by Cap. -0.26%+5.40%+43.93%+72.03%

Financials

2026 *2027 *
Net sales 57.65B 49.42B 46.25B 42.28B 79.79B 5,519B 80.65B 547B 213B 2,771B 216B 212B 9,170B 61.31B 52.56B 49.19B 44.97B 84.86B 5,869B 85.77B 582B 226B 2,947B 230B 225B 9,752B
Net income 13.95B 11.96B 11.19B 10.23B 19.31B 1,336B 19.52B 132B 51.45B 671B 52.38B 51.24B 2,219B 15.5B 13.29B 12.44B 11.37B 21.46B 1,484B 21.69B 147B 57.17B 745B 58.2B 56.94B 2,466B
Net Debt 32.68B 28.02B 26.22B 23.97B 45.23B 3,129B 45.72B 310B 121B 1,571B 123B 120B 5,198B 27.82B 23.85B 22.32B 20.4B 38.5B 2,663B 38.92B 264B 103B 1,337B 104B 102B 4,425B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
75,267
Date Price Change Volume
26-08-24 US$158.02 -0.53% 801,029
26-08-21 US$158.86 +1.68% 1,183,728
26-08-20 US$156.24 -2.54% 1,525,742
26-08-19 US$160.31 +3.73% 2,400,550
26-08-18 US$154.55 +1.70% 1,412,922
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
158.11USD
Average target price
154.32USD
Spread / Average Target
-2.39%

Quarterly revenue - Rate of surprise